WHWK Stock — Whitehawk Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.

Source: 10-K FY2025 via SEC EDGAR

Share price

$3.13

Market cap

$178.4M

Cash

$190.0M

Enterprise value

-$11.6M

Balance sheet

Cash	$190.0M
Debt	$0.0M
Net cash	$190.0M
Enterprise value	-$11.6M
Basic shares	57.0M shares
Fully diluted shares	93.9M shares
Fully diluted market cap	$293.8M
Cash per share	$3.33
Quarterly burn	$14.5M
Cash runway	13.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

57.0M

Pre-funded warrants

36.9M

Options

—

RSUs

0.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

93.9M

Cap table as of 2026-08-03.

Price history

Loading WHWK daily closes…

Loading price history…

Next catalyst

HWK-007 · Est. Apr 1, 2027 · half midpoint · guided in 8 wks

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	HWK-007 Phase 1 trial of HWK-007: initial results	Phase 1	Not disclosed	1H 2027
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	HWK-016 Phase 1 trial of HWK-016: initial results	Phase 1	Not disclosed	1H 2027
Mar 14 - Apr 25 in 16 mo	HWK-016, MUCIN-16-targeted ADC	Phase 1	PROC; Platinum Resistant Ovarian Cancer; Endometrial Cancer	—
Nov 12 - Dec 24 in 25 mo	HWK-007	Phase 1	Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

HWK-007

Phase 1 · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target PTK7

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024); milestones up to $265M development + $540M commercial plus royalties. Hangzhou DAC: CPT113 linker-payload technology

Indications

Non-small cell lung cancer (NSCLC) (Phase 1)
Ovarian cancer (Phase 1)
Endometrial cancer (Phase 1)

Catalysts

— H1 2027

Status note PTK7-directed ADC. IND cleared; Phase 1 HWK-007-101 actively recruiting adults with advanced or metastatic solid tumors refractory to standard therapies.

HWK-016

Phase 1 · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target MUC16

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024); milestones up to $265M development + $540M commercial plus royalties. Hangzhou DAC: CPT113 linker-payload technology

Indications

Ovarian cancer (Phase 1)
Endometrial cancer (Phase 1)

Catalysts

— H1 2027

Status note MUC16-directed ADC. IND cleared; Phase 1 HWK-016-101 actively recruiting.

HWK-206

Preclinical · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target SEZ6

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024). Hangzhou DAC: CPT113 linker-payload technology; May 2026 option agreement for up to five additional ADC programs

Indications

Small cell lung cancer (SCLC) (Preclinical)
Neuroendocrine tumors (NETs) (Preclinical)

Catalysts

— mid-2026

Status note Biparatopic SEZ6-directed ADC. IND-enabling studies underway; IND submitted with FDA clearance anticipated mid-2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	HWK-016, MUCIN-16-targeted ADC
Lead indication	PROC
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07470853	Phase 1	Recruiting	Sponsor	WHWK	—	PROC; Platinum Resistant Ovarian Cancer; Endometrial Cancer	1H 2027 Est. Apr 1, 2027 · half midpoint
NCT07444814	Phase 1	Recruiting	Sponsor	WHWK	—	Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic	1H 2027 Est. Apr 1, 2027 · half midpoint

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Whitehawk Therapeutics, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,934,296	-231,704	0.34%	2026-08-14
Avoro Capital Advisors	2,849,402	no change	0.12%	2026-08-14
ADAR1 Capital Management	1,341,394	+1,212,891	0.29%	2026-08-14
Ally Bridge Group	817,939	no change	4.83%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

WHWK — Whitehawk Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

WHWK — Whitehawk Therapeutics Inc.